Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
12/5/23 | Merck KGaA (MKKGY) | Evobrutinib for Multiple Sclerosis (MS) | Subscribers Only | Subscribers Only | Subscribers Only |
12/5/23 | Roche (RHHBY) | Inavolisib for HR+/HER2- Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
12/4/23 | Alto Neuroscience | ALTO-300 for Major Depressive Disorder (MDD) | Subscribers Only | Subscribers Only | Subscribers Only |
12/1/23 | Pfizer (PFE) | Danuglipron for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
11/30/23 | CG Oncology | CG0070 for Bladder Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
12/08/23 | Subscribers Only | Subscribers Only | Trial Data - Final Results |
12/08/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
12/08/23 | Subscribers Only | Subscribers Only | Trial Data - Other |
12/08/23 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
Now - 12/09/23 | Subscribers Only | Subscribers Only | Trial Data - Other |